Literature DB >> 991541

Artificial kidneys and clearance calculations.

T P Gibson, E Matusik, L D Nelson, W A Briggs.   

Abstract

Clearance of solutes by artificial kidneys can be calculated using plasma flow and solute concentration, whole blood flow and plasma solute concentration, and midpoint of dialysis blood or plasma solute concentration and total amount of solute removed. Using these methods, the clearance of procainamide (PA) and N-acetylprocainamide (NAPA) was determined in 4 patients. In all but one case clearances using total amount recovered were greater than clearances using whole blood flow and plasma concentration. Without exception, clearance determined using amount recovered was substantially greater than clearance using plasma flow and plasma levels, suggesting that both PA and NAPA are removed not only from plasma but also from red blood cells. In vitro clearance of PA, NAPA, quinidine, and phenobarbital by 11 clinically available artificial kidneys and an XAD-4 hemoperfusion column was determined and differences were found.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 991541     DOI: 10.1002/cpt1976206720

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

1.  Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.

Authors:  R A Blum; R K Kohli; N J Harrison; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 3.  Pharmacokinetics of haemoperfusion for drug overdose.

Authors:  S Pond; J Rosenberg; N L Benowitz; S Takki
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

4.  Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vincon; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Drug dosage in end-stage renal disease (ESRD) patients undergoing haemodialysis. A predictive study based on a microcomputer program.

Authors:  M V Mac-Kay; J Sanchez Burson; J Martinez-Lanao; A Dominguez-Gil
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

6.  Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.

Authors:  D E Uehlinger; F Schaedeli; M Kinzig; F Sörgel; F J Frey
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Authors:  B Flouvat; S Decourt; P Aubert; L Potaux; M Domart; A Goupil; A Baglin
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

8.  Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.

Authors:  R Larsson; P Erlanson; G Bodemar; B Norlander; L Fransson; L Strouth
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Disposition and removal of metronidazole in patients undergoing haemodialysis.

Authors:  A Somogyi; C Kong; J Sabto; F W Gurr; W J Spicer; A J McLean
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.